FDA Accelerated Approval Faces Transparency Crisis

What Is FDA Accelerated Approval and Why Is Transparency a Concern?

The FDA's accelerated approval pathway was created in 1992 to speed access to drugs treating serious conditions where unmet medical need is high. Rather than requiring direct evidence of clinical benefit such as improved survival, the agency may grant approval based on surrogate endpoints — measurable markers like tumor shrinkage or biomarker changes that are reasonably likely to predict real-world outcomes. Sponsors are then required to conduct post-marketing confirmatory trials to verify clinical benefit.

The transparency concerns highlighted in recent research center on how outcomes from these confirmatory trials are reported, how long verification takes, and what happens when surrogate endpoints fail to translate into meaningful patient benefit. Independent analyses, including work published in JAMA and BMJ over recent years, have repeatedly found that a substantial share of accelerated-approval drugs remain on the market for extended periods before confirmatory data emerge — and in some cases, drugs receive full approval despite confirmatory trials showing limited or no clinical benefit.

How Does the FDA Use Surrogate Endpoints in Drug Approval?

Surrogate endpoints span oncology, infectious disease, and rare disease drug development. In cancer, common surrogates include progression-free survival, objective response rate, and minimal residual disease status. In HIV therapy, viral load reduction has long served as an accepted surrogate. The strength of the link between surrogate and clinical outcome varies considerably across disease areas, and this is where transparency becomes critical: clinicians and patients need clear information about how reliably a given surrogate predicts survival or quality-of-life improvements.

The Food and Drug Omnibus Reform Act of 2022 (FDORA) gave the FDA strengthened authority to require confirmatory trials to be underway at the time of accelerated approval and to expedite withdrawal of drugs that fail to verify benefit. However, researchers continue to press for public dashboards, standardized reporting timelines, and clearer disclosures about which approvals rest on weaker surrogate evidence — all aimed at helping prescribers and patients make better-informed treatment choices.

What Reforms Are Researchers Recommending?

Recommendations from health policy researchers and organizations such as the Institute for Clinical and Economic Review and academic groups at Harvard, Yale, and Johns Hopkins generally cluster around several reforms. These include public-facing tracking of confirmatory trial enrollment and completion timelines, stricter consequences when trials are delayed without justification, and clearer labeling that distinguishes accelerated from traditional approvals at the point of prescribing.

Patient advocacy groups have offered a more nuanced view: while faster access remains essential — especially for terminal cancers and rare diseases with no alternatives — they support reforms that ensure post-market evidence is generated rigorously and shared openly. The ongoing debate reflects a fundamental tension in modern drug regulation between speed of access and certainty of benefit, a balance the FDA continues to recalibrate as it implements FDORA provisions.